Nemolizumab with concomitant topical therapy in adolescents and adults with moderate-to-severe atopic dermatitis (ARCADIA 1 and ARCADIA 2): results from two replicate, double-blind, randomised controlled phase 3 trials
Jonathan I. Silverberg(George Washington University), Christophe Piketty(Galderma (Switzerland)), Andrew Pink, Kamila Padlewska(Ocná klinika), Soo Yeon Cheong(Galderma (United States)), Barbara Rewerska(Krakow Cardiovascular Research Institute), Nina Magnolo(University Hospital Münster), Linda Stein Gold(Henry Ford Health System), Vipul Jain(MIT University), Liliana Ulianov(Galderma (Switzerland)), J.M. Carrascosa(Hospital Universitari Germans Trias i Pujol), Dorota Krasowska(Medical University of Lublin), Sylvia Pauser(Osnabrück University), Adam Reich(Rzeszów University of Technology), Franz J. Legat(Medical University of Graz), Blanka Havlíčková(Ocní klinika), Andreas Wollenberg(University Hospital Augsburg), Jacek C. Szepietowski(Wroclaw Medical University), Maxwell Sauder(Johns Hopkins University), Jean‐David Bouaziz(Université Paris Cité), Navid Nami(Los Angeles Clinical Trials), Diamant Thaçi(University of Lübeck), Kim Papp(University of Toronto), Patricia Fleuranceau Morel(Galderma (United States)), Monika Kalowska(Institute of Psychiatry and Neurology)
Cited by 144
Related Papers
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
|New England Journal of Medicine|2016|2k
The Psychological Burden of Skin Diseases: A Cross-Sectional Multicenter Study among Dermatological Out-Patients in 13 European Countries
|Journal of Investigative Dermatology|2014|954
Definition of treatment goals for moderate to severe psoriasis: a European consensus
|Archives of Dermatological Research|2010|892
Clinical Classification of Itch: a Position Paper of the International Forum for the Study of Itch
|Acta Dermato Venereologica|2007|748